TABLE 3.
Pretreatment Predictors of Early (Premaintenance) Biochemical Outcomes
| Baseline Characteristic | Odds Ratio | 95% CI | P |
|---|---|---|---|
| Biochemical nonresponse (<50% reduction from baseline fecal calprotectin) | |||
| ≤10-y-old starting infliximab | 1.9 | 0.44–9.1 | 0.40 |
| wPCDAI > 40 | 0.9 | 0.23–3.4 | 0.88 |
| ESR ≥ 20 mm/h | 1.5 | 0.33–7.5 | 0.58 |
| CRP ≥ 5 mg/dL | 5.5 | 0.72–115 | 0.15 |
| Albumin ≤ 3.5 g/dL | 6.2 | 1.2–48 | 0.042 |
| OSMhigh (≥143.5 pg/mL) | 8.4 | 2–43 | 0.006 |
| nCD64high (>1.07) | 2.8 | 0.61–15 | 0.21 |
| OSMhigh + nCD64high | 13.3 | 2.6–106 | 0.005 |
| Biochemical nonremission (fecal calprotectin > 250 µg/g) | |||
| Albumin ≤ 3.5 g/dL | 19 | 3.4–165 | 0.002 |
| OSMhigh (≥143.5 pg/mL) | 3.9 | 0.90–21 | 0.084 |
| nCD64high (>1.07) | 8.9 | 1.8–55 | 0.011 |
| OSMhigh + nCD64high | 11 | 1.7–219 | 0.034 |
CRP, c-reactive protein; ESR, erythrocyte sedimentation rate.